Credit Suisse analyst Trung Huynh has combed through social media and is impressed by the awareness — and demand — for GLP-1 medications such as Eli Lilly 's Mounjaro.
Among those observations are reports of other potential benefits that patients taking Mounjaro, or tirzepatide, are seeing.
Others taking the drug reported benefits such as a reduction in addiction behaviors such as smoking, drinking, gambling and shopping, among other things.
However, this may be a function of patients who are trying to use Mounjaro off-label for obesity, he said.
Credit Suisse has an outperform rating on Lilly shares, with a $490 price target, which implies more than 9% upside from where Lilly shares closed Wednesday.
Persons:
Trung Huynh, Eli Lilly, Huynh, Mounjaro, agonism, Lilly hasn't, semaglutide —, Lilly, —, Michael Bloom
Organizations:
Credit Suisse, Food and Drug Administration, Novo Nordisk